[
  {
    "ts": "2025-09-17T13:40:02+00:00",
    "headline": "Why Amgen (AMGN) is a Top Value Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/why-amgen-amgn-top-value-134002943.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "be6930cc-8dc0-3c7f-8356-575e5caa484e",
      "content": {
        "id": "be6930cc-8dc0-3c7f-8356-575e5caa484e",
        "contentType": "STORY",
        "title": "Why Amgen (AMGN) is a Top Value Stock for the Long-Term",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2025-09-17T13:40:02Z",
        "displayTime": "2025-09-17T13:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0",
          "originalWidth": 3000,
          "originalHeight": 2351,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/22J0oUBDggIxRsu_SBEo3A--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0.cf.webp",
              "width": 3000,
              "height": 2351,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/c871s3MwhyhBJ_fCBFL4cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-amgn-top-value-134002943.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-amgen-amgn-top-value-134002943.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-17T06:30:00+00:00",
    "headline": "Ollin debuts with $100M and plans to challenge top-selling eye drugs",
    "summary": "Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.",
    "url": "https://www.biopharmadive.com/news/ollin-biosciences-ophthalmology-startup-vabysmo-tepezza/760182/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "7080f7b0-5ef7-3bd5-9e26-79d04edd3fcf",
      "content": {
        "id": "7080f7b0-5ef7-3bd5-9e26-79d04edd3fcf",
        "contentType": "STORY",
        "title": "Ollin debuts with $100M and plans to challenge top-selling eye drugs",
        "description": "",
        "summary": "Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.",
        "pubDate": "2025-09-17T06:30:00Z",
        "displayTime": "2025-09-17T06:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/ea66270f27b464162a03fec5989a497b",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "Associated with age-related macular degeneration, geographic atrophy causes irreversible vision loss.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MthDhD8vVv23qPTlQF2a.g--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/ea66270f27b464162a03fec5989a497b.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iasxXGHKDeWcfts4Xl_m8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/ea66270f27b464162a03fec5989a497b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/ollin-biosciences-ophthalmology-startup-vabysmo-tepezza/760182/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ollin-debuts-100m-plans-challenge-063000657.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "1801.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]